LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a product name.
REQUEST A FREE TRIAL
Product
Deals
Articles
BioCentury
|
Feb 19, 2020
Product Development
COVID-19 update: Sanofi enters vaccine race with BARDA collaboration; plus J&J-BARDA expansion, clinical and diagnostic advances, and more
Read More
BioCentury
|
Aug 3, 2018
Clinical News
Merck's doravirine similar to ritonavir-boosted darunavir in Phase III for HIV-1 infection
Read More
BioCentury
|
Jul 20, 2018
Clinical News
FDA approves J&J's Symtuza for HIV-1 infection in adults
Read More
BioCentury
|
Jun 13, 2018
Distillery Therapeutics
Infectious disease
Read More
BioCentury
|
Feb 17, 2018
Politics, Policy & Law
FDA’s bigger piggy bank
How FDA plans to spend a proposed $400 million budget boost
Read More
BioCentury
|
Nov 15, 2017
Distillery Therapeutics
Infectious disease
Read More
BioCentury
|
Oct 27, 2017
Clinical News
EC approves Symtuza for HIV-1, Janssen submits NDA to FDA
Read More
BioCentury
|
Jun 29, 2017
Strategy
Lilly goes with the flow
Lilly joins the continuous manufacturing bandwagon with a CGMP process.
Read More
BioCentury
|
Jun 2, 2017
Clinical News
Gilead reports Phase III data for HIV combo in virologically suppressed patients
Read More
BioCentury
|
May 30, 2017
Clinical News
Gilead’s HIV combo non-inferior in four Phase III trials
Read More
Items per page:
10
1 - 10 of 110